Loading…
Roivant Sciences Ltd. is projected to rise to $43.39 by 2027, a +32% move from its current price of $32.87. ROIV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/30/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $32.30 | $32.87 | $33.45 | 0.00% |
| Aug 1 | $32.07 | $32.87 | $33.69 | 0.00% |
| Aug 2 | $31.90 | $32.87 | $33.88 | 0.00% |
| Aug 3 | $31.75 | $32.87 | $34.04 | +0.01% |
| Aug 4 | $31.62 | $32.87 | $34.18 | +0.01% |
| Aug 5 | $31.50 | $32.87 | $34.30 | +0.01% |
| Aug 6 | $31.40 | $32.87 | $34.42 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.40 | $32.87 | $34.42 | +0.01% |
| Week 2 | $30.81 | $32.88 | $35.09 | +0.02% |
| Week 3 | $30.36 | $32.88 | $35.61 | +0.03% |
| Week 4 | $29.99 | $32.88 | $36.05 | +0.04% |
| Week 5 | $29.67 | $32.89 | $36.45 | +0.06% |
| Week 6 | $29.39 | $32.89 | $36.81 | +0.07% |
| Week 7 | $29.13 | $32.90 | $37.15 | +0.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of medicines and technologies.
Its clinical product candidates include IMVT-1402, mosliciguat, neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. It also offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform.
Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd. (ROIV) is trading at $33.93 per share, with a market capitalization of $24.4B. It is ranked 520.
The current price outlook is supported by a multi-year forecast showing an upward path. For 2026, the average price is $33.93 with 0% ROI; 2027 average $44.99 with 32.6% ROI; 2028 average $57.69 with 70% ROI; 2029 average $64.97 with 91.5% ROI; and 2030 average $74.11 with 118.4% ROI.
A major floor 19.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.5% below — buyers have tended to step in here.
The nearest ceiling, 12.0% above — a clean break opens room to run.
A major ceiling 21.0% above — clearing it would confirm fresh momentum.
Key ROIV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ROIV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.31 | Sell | $33.96 | Sell |
| MA 10 | $34.39 | Sell | $34.32 | Sell |
| MA 20 | $34.95 | Sell | $34.25 | Sell |
| MA 50 | $32.33 | Buy | $32.74 | Buy |
| MA 100 | $30.35 | Buy | $30.46 | Buy |
| MA 200 | $26.24 | Buy | $26.60 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.61 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -218.75 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.38 | Sell |
| ROC (12) | -4.75 | Sell |
| Bollinger %B (20,2) | -0.08 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.36 | Buy |
| Awesome (5,34) | 0.61 | Buy |
| Ultimate (7,14,28) | 33.86 | Neutral |
| Momentum (10) | -2.02 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 33.89 | Sell |
| ADX (14) | 20.81 | Sell |
| ATR (14) | 0.55 | Info |
The 30-day technical picture is BULLISH, with RSI(14) at 50. The SMA50 is $31.34 and the SMA200 is $25.41. Support sits at $28.41 and resistance at $36.81. The 30-day price range runs from $30.01 to $38.36, with an annualized volatility of 40%.
This snapshot provides a concise view of near-term dynamics and key levels to watch.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.14 | $32.87 | $41.85 | 0% | Neutral | |
| $35.58 | $43.39 | $55.31 | +32% | Bullish | |
| $44.69 | $55.55 | $72.74 | +69% | Bullish | |
| $50.81 | $64.14 | $85.79 | +95% | Bullish | |
| $56.44 | $72.21 | $98.35 | +120% | Bullish | |
| $61.39 | $79.50 | $110.00 | +142% | Bullish | |
| $68.17 | $89.29 | $125.31 | +172% | Bullish | |
| $75.07 | $99.36 | $141.26 | +202% | Bullish | |
| $89.37 | $119.46 | $171.87 | +263% | Bullish | |
| $106.10 | $143.18 | $208.30 | +336% | Bullish | |
| $156.58 | $220.40 | $336.05 | +571% | Bullish | |
| $277.13 | $418.40 | $683.92 | +11.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $21.14 | $32.87 | $38.41 | +0.00% |
| August 2026 | $28.72 | $33.50 | $39.82 | +1.90% |
| September 2026 | $28.06 | $32.92 | $39.49 | -1.73% |
| October 2026 | $27.68 | $32.61 | $39.42 | -0.93% |
| November 2026 | $28.39 | $33.57 | $40.82 | +2.95% |
| December 2026 | $28.85 | $34.23 | $41.85 | +1.97% |
Click any year to see its month-by-month ROIV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ROIV to range from $21.14 to $41.85 through 2026. The $32.87 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ROIV price prediction for 2027 points to an average of $43.39 (low $35.58, high $55.31) — a potential gain of +32% on today's $32.87. Momentum favours further upside here.
In 2028, ROIV is projected to trade between $44.69 and $72.74, averaging $55.55 — a potential gain of +69% from today's $32.87. That is up +28% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Roivant Sciences Ltd.'s 2029 outlook centres on $64.14, within a $50.81 to $85.79 range. That is up +15% on the projected 2028 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2030, ROIV could reach as high as $98.35, with a base case around $72.21 and support toward $56.44 — roughly +120% from $32.87. Buyers look set to stay in control over this stretch.
Expect ROIV to range from $61.39 to $110.00 through 2031. The $79.50 average target implies a +142% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The ROIV price prediction for 2032 points to an average of $89.29 (low $68.17, high $125.31) — a potential gain of +172% on today's $32.87. Buyers look set to stay in control over this stretch.
In 2033, ROIV is projected to trade between $75.07 and $141.26, averaging $99.36 — a potential gain of +202% from today's $32.87. That is up +11% on the projected 2032 average. Momentum favours further upside here.
Roivant Sciences Ltd.'s 2034 outlook centres on $119.46, within a $89.37 to $171.87 range. That is up +20% on the projected 2033 average. That marks a +263% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ROIV could reach as high as $208.30, with a base case around $143.18 and support toward $106.10 — roughly +336% from $32.87. Momentum favours further upside here.
Expect ROIV to range from $156.58 to $336.05 through 2040. The $220.40 average target implies a +571% move from current prices. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ROIV price prediction for 2050 points to an average of $418.40 (low $277.13, high $683.92) — a potential gain of +11.7x on today's $32.87. Momentum favours further upside here.
Investing $1,000 in ROIV today (≈ 30.422878 ROIV) could be worth
$12,728.93
+$11,728.93 (+1173%) by 2050 · US Dollar
Based on the average projected ROIV price of $418.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ROIVwould be worth at today's price.
$1,000 invested in ROIV on Jul 29, 2025 (≈ 87.565674 ROIV) would be worth
$2,878.28
+$1,878.28 (+187.8%) today · 2.88× · US Dollar
Based on a ROIV entry price of $11.42 vs. today's $32.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.91 | $941.56 | -5.8% |
| 1 month ago | $34.73 | $946.44 | -5.4% |
| 3 months ago | $28.53 | $1,152.12 | +15.2% |
| 6 months ago | $21.62 | $1,520.35 | +52.0% |
| 1 year ago | $11.42 | $2,878.28 | +187.8% |
| All time (5.0y) ago | $9.89 | $3,323.56 | +232.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ROIV forecast.
Our base-case forecast reaches $66.00 around 2030.
Implied market cap at $66.00: $47.47B
The multi-year forecast shows an ongoing uptrend. The 2026 average price is $33.93 with 0% ROI, and 2027 averages $44.99 with 32.6% ROI; 2028 averages $57.69 with 70% ROI; 2029 averages $64.97 with 91.5% ROI; and 2030 averages $74.11 with 118.4% ROI.
Beyond 2030 the average rises to 2031 $82.04; 2032 $89.54; 2033 $101.36; 2034 $122.65; 2035 $143.77; 2040 $222.63; and 2050 $415.23. Max values accompany the forecasts, e.g., 2030 max $101.00; 2040 max $339.55; 2050 max $678.88. ROI climbs to 141.8% in 2031, 163.9% in 2032, 198.7% in 2033, 261.5% in 2034, 323.7% in 2035, 556.1% in 2040, and 1123.8% in 2050.
Sentiment is BULLISH from 2027 onward, with 2026 labeled NEUTRAL. These figures are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
Avg $74.11; min $57.90; max $101.00; ROI 118.4%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with average prices rising to $74.11 by 2030 and $415.23 by 2050; ROI to 1123.8% by 2050. These are estimates, not guarantees.
Yes. The 2030 max is $101.00, and the 2033 max is $144.17, so reaching $100 is within the forecast.
Current price is $33.93 and market capitalization is $24.4B.
30-day range low $30.01 and high $38.36.
Roivant Sciences Ltd. Community Discussion
0Share your Roivant Sciences Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.